Targeting translation: EIF4E as an emerging anticancer drug target

Chunwan Lu, Levi Makala, Daqing Wu, Yafei Cai

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

The translation initiation factor eIF4E mediates a rate-limiting process that drives selective translation of many oncongenic proteins such as cyclin D1, survivin and VEGF, thereby contributing to tumour growth, metastasis and therapy resistance. As an essential regulatory hub in cancer signalling network, many oncogenic signalling pathways appear to converge on eIF4E. Therefore, targeting eIF4E-mediated cap-dependent translation is considered a promising anticancer strategy. This paper reviews the strategies that can be used to target eIF4E, highlighting agents that target eIF4E activity at each distinct level.

Original languageEnglish (US)
Article numbere2
JournalExpert Reviews in Molecular Medicine
Volume18
DOIs
StatePublished - Jan 18 2016

Fingerprint

Eukaryotic Initiation Factor-4E
Peptide Initiation Factors
Cyclin D1
Pharmaceutical Preparations
Vascular Endothelial Growth Factor A
Neoplasms
Neoplasm Metastasis
Growth
Proteins
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

Targeting translation : EIF4E as an emerging anticancer drug target. / Lu, Chunwan; Makala, Levi; Wu, Daqing; Cai, Yafei.

In: Expert Reviews in Molecular Medicine, Vol. 18, e2, 18.01.2016.

Research output: Contribution to journalReview article

@article{b678a254822c430dbbb54b6dbdc610e9,
title = "Targeting translation: EIF4E as an emerging anticancer drug target",
abstract = "The translation initiation factor eIF4E mediates a rate-limiting process that drives selective translation of many oncongenic proteins such as cyclin D1, survivin and VEGF, thereby contributing to tumour growth, metastasis and therapy resistance. As an essential regulatory hub in cancer signalling network, many oncogenic signalling pathways appear to converge on eIF4E. Therefore, targeting eIF4E-mediated cap-dependent translation is considered a promising anticancer strategy. This paper reviews the strategies that can be used to target eIF4E, highlighting agents that target eIF4E activity at each distinct level.",
author = "Chunwan Lu and Levi Makala and Daqing Wu and Yafei Cai",
year = "2016",
month = "1",
day = "18",
doi = "10.1017/erm.2015.20",
language = "English (US)",
volume = "18",
journal = "Expert Reviews in Molecular Medicine",
issn = "1462-3994",
publisher = "Cambridge University Press",

}

TY - JOUR

T1 - Targeting translation

T2 - EIF4E as an emerging anticancer drug target

AU - Lu, Chunwan

AU - Makala, Levi

AU - Wu, Daqing

AU - Cai, Yafei

PY - 2016/1/18

Y1 - 2016/1/18

N2 - The translation initiation factor eIF4E mediates a rate-limiting process that drives selective translation of many oncongenic proteins such as cyclin D1, survivin and VEGF, thereby contributing to tumour growth, metastasis and therapy resistance. As an essential regulatory hub in cancer signalling network, many oncogenic signalling pathways appear to converge on eIF4E. Therefore, targeting eIF4E-mediated cap-dependent translation is considered a promising anticancer strategy. This paper reviews the strategies that can be used to target eIF4E, highlighting agents that target eIF4E activity at each distinct level.

AB - The translation initiation factor eIF4E mediates a rate-limiting process that drives selective translation of many oncongenic proteins such as cyclin D1, survivin and VEGF, thereby contributing to tumour growth, metastasis and therapy resistance. As an essential regulatory hub in cancer signalling network, many oncogenic signalling pathways appear to converge on eIF4E. Therefore, targeting eIF4E-mediated cap-dependent translation is considered a promising anticancer strategy. This paper reviews the strategies that can be used to target eIF4E, highlighting agents that target eIF4E activity at each distinct level.

UR - http://www.scopus.com/inward/record.url?scp=84955209824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955209824&partnerID=8YFLogxK

U2 - 10.1017/erm.2015.20

DO - 10.1017/erm.2015.20

M3 - Review article

C2 - 26775675

AN - SCOPUS:84955209824

VL - 18

JO - Expert Reviews in Molecular Medicine

JF - Expert Reviews in Molecular Medicine

SN - 1462-3994

M1 - e2

ER -